Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Connect Biopharma Holdings Ltd CNTB

Healthcare Biotechnology
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company focused on improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. It is building a pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates... see more

Recent & Breaking News (NDAQ:CNTB)

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire April 16, 2024

Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

GlobeNewswire March 19, 2024

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

GlobeNewswire February 12, 2024

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

GlobeNewswire December 12, 2023

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

GlobeNewswire December 11, 2023

Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management

Newsfile November 30, 2023

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

GlobeNewswire November 21, 2023

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

GlobeNewswire November 21, 2023

Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023

GlobeNewswire November 20, 2023

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

GlobeNewswire September 12, 2023

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

GlobeNewswire September 12, 2023

Connect Biopharma to Participate in Upcoming September Investor Conferences

GlobeNewswire August 24, 2023

Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology

GlobeNewswire July 10, 2023

Connect Biopharma to Participate in the SVB Securities Therapeutics Forum

GlobeNewswire July 5, 2023

Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis

GlobeNewswire June 1, 2023

Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update

GlobeNewswire April 11, 2023

Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms

Business Wire March 18, 2023

Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions

Business Wire March 17, 2023

Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Business Wire March 6, 2023

Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California

GlobeNewswire February 6, 2023